(%)100*1*241(Millions of yen)120,000(Millions of yen)200,000100,000150,000100,00087,09292,14388,49983,09787,09292,14388,49983,097408.8408.880,000429.3429.360,000378.1378.1305.4305.428,97628,97640,00023,03623,03621,46121,46120,32921,25419,54920,32921,25419,54920,0002016201720182019143,286143,286142,908151,394142,908151,39484.184.1137,554137,55469.769.7145,096145,09672.172.177.177.1108,985108,985127,825127,82550,000120,217120,217110,478110,47899,98499,9842016201720182019（%）600115,439115,43997,32597,325590.5590.5500457.9457.94003002001002020202100000164,257164,25783.783.786.386.38060142,857142,85740202020202160,00050,00040,00031,91130,00020,000* Effect of exchange rate change on cash and cash equivalents (25 million yen) is included in Balance at end of period. 20,042(4,817)(686)46,475* Effect of exchange rate change on cash and cash equivalents (169 million yen) is included in Balance at end of period. *1 We proactively implemented strategic corporate alliances and the introduction of R&D products in order to further increase corporate value by expanding our business. *2 New buildings were constructed at the main plants, Hikone and Nagahama, to ensure the quality of pharmaceutical products and stabilize supply.164,257（+12,863）Capital expenditure / DepreciationCash and deposits（+12,571）Notes and accountsreceivable–trade（+2,270）Current assets115,439（+18,113）AssetsNon-current assets48,818（-5,250）Depreciation（-5,997）(Millions of yen)70,000Balance at beginning of periodOperatingactivities(Millions of yen)15,000■Capital expenditure ■Depreciation13,55418,06360,00050,00046,47540,00030,00020,00010,94010,0006,8575,0005,0145,0146,3496,349201620172018(4,591)(570)59,5477,4317,4316,9376,5335,9977,3187,3183,5313,5312,6842,68420192020202119,549（-1,704）Total net assets / Total assets / Equity-to-asset ratioCurrent assets / Current liabilities / Current ratioOverview of Consolidated Balance Sheet151,394Overview of Consolidated Statement of Cash Flows■Current assets ■Current liabilities● Current ratio■Total net assets ■Total assets● Equity-to-asset ratioAssets(Millions of yen)70,000Balance at beginning of period(Millions of yen)Current liabilitiesLiabilities21,400（-2,168）Non-current liabilities1,850（-463）Equity attributable to owners141,777（+15,004）Net assets142,857（+15,031）Non-controllinginterests1,080（+27）Retained earnings（+14,769）InvestingactivitiesFinancingactivitiesBalance atend of periodat the end of the consolidated fiscal year under review was 59,547 million yen (up 28.1% from the previous fiscal year). Cash flows from operating activities decreased 9.9% from the previous fiscal year, to 18,063 million yen. This was due to a decrease of 2,308 million yen resulting from the increase in trade receivables, as well as profit before income taxes of 21,134 million yen and the recording of non-cash items such as Depreciation of goodwill. Cash flows from investing activities decreased 4.7% from the previous fiscal year, to 4,591 million yen, mainly due to capital investment and purchase of intangible assets. Cash flows from financing activities decreased 17.0% from the previous fiscal year, to 570 million yen. The Maruho Group’s demand for funds is mainly for the purpose of investment in research and development, as well as carried out an acquisition of manufacturing equipment for the Hikone Plant, our base of manufacturing for pharmaceuticals; renovation of the existing building of the equipment for the Kyoto R&D Center; Nagahama Plant; acquisition of experimental ■Cash flowsThe balance of cash and cash equivalents ■Capital expenditure, etc. (Tangible assets and intangible assets)During the fiscal year under review, we investments in tangible/intangible fixed assets, such as construction of new manufacturing facilities, enhancement of R&D functions, and acquisition of sales rights. The Maruho Group ensures a level of cash and deposits sufficient not only to finance these investments but also to respond to certain strategic investment opportunities.introduction of software to improve internal work efficiency; and acquisition of the sales rights related to introduction of R&D products. We will continue to pay attention to trends in the market and make focused, strategic investments, with the aim of taking every opportunity for growth. Incidentally, the Maruho Group has been rated “A-” by Rating and Investment Information, Inc. (R&I) as of September 30, 2021. We have also established commitment lines totaling 10 billion yen with financial institutions in Japan, making us prepared for liquidity support. 2020.92020.9Currentliabilities21,254Liabilities23,568Non-current liabilities2,313Current assets97,325Equity attributable to owners126,772Net assets127,825Non-current assets54,068Non-controllinginterests1,053OperatingactivitiesInvestingactivitiesFinancingactivitiesBalance atend of period2021.92021.9
元のページ ../index.html#43